CoLucid Pharmaceuticals (CLCD) Results Reduce Clinical and Regulatory Risk - Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
CoLucid Pharmaceuticals' (CLCD) Price Target Raised to $52 at Ladenburg Thalmann
September 6, 2016 9:10 AM EDTLadenburg Thalmann maintained a Buy rating on CoLucid Pharmaceuticals (NASDAQ: CLCD) and raised its price target to $52.00 (from $23.00)
For an analyst ratings summary and ratings history on CoLucid Pharmaceuticals click here. For more ratings news on CoLucid Pharmaceuticals click here.
Shares of CoLucid Pharmaceuticals closed at $10.66 yesterday.
... MoreCoLucid Pharmaceuticals' (CLCD) SAMURAI Phase 3 Trial of Lasmiditan in Migraine Meets Primary and Secondary Endpoints
September 6, 2016 7:50 AM EDTCoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of migraine in adults, with or without aura, announced today that its Phase 3 pivotal study evaluating lasmiditan, the SAMURAI study, achieved both the primary and key secondary efficacy endpoints with statistical significance (p... More
